A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Study on Chronic Lung Allograft Dysfunction Treatment in Adults

Recruiting
18 years or above
All
Phase 3
180 participants needed
32 Locations

Study Overview

This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy.

Study details include:

The study duration will be up to 31 weeks for participants not entering the open-label extension (OLE) period and up to 57 weeks for participants entering the OLE period but not the long-term OLE.

The treatment duration will be up to 26 weeks for participants not entering the OLE period and up to 52 weeks for participants entering the OLE period but not the long-term OLE.

The number of visits will be up to 10 visits for participants not entering the OLE period and up to 16 visits for participants entering the OLE period but not the long-term OLE.

For participants who enter the long-term OLE, treatment and study participation will continue with visits every 12 weeks per protocol specifications.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lung Transplant Rejection
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  • Participant ≥1 year post bilateral lung transplantation at the time of screening
  • Participants presenting with CLAD Stage 1 or 2: FEV1 from >50% to 80% of post-transplant baseline at screening and at randomization
  • Participants who have received at least 8 weeks of azithromycin (≥250 mg/day, at least 3 times a week) prior to randomization

Exclusion Criteria:

  • FEV1 ≤50% of the post-transplant baseline value (CLAD 3 and 4)
  • Lung function decline that can be explained by non-CLAD causes including but not limited to acute lung allograft rejection (>A1), antibody-mediated rejection, airway stenosis, or tracheobronchomalacia

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

This study investigates the effectiveness of an investigational medication for treating chronic lung allograft dysfunction (CLAD) in adults. The purpose of this study is to evaluate the safety and effectiveness of the investigational medication in comparison to a placebo. The study will focus on understanding how well the treatment works and how safe it is for participants who have already been receiving azithromycin and immunosuppressive therapy.

  • Who can participate: Participants must be 18 years or older and at least one year post bilateral lung transplant. They should have CLAD Stage 1 or 2 and have been on azithromycin for at least 8 weeks before joining the study.
  • Study details: Participants will take part in a study where some will receive an investigational medication and others a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
Updated on 02 Apr 2026. Study ID: NCT06082037

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language